Norris Medicines Past Earnings Performance
Past criteria checks 0/6
Norris Medicines's earnings have been declining at an average annual rate of -4.2%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 14.5% per year.
Key information
-4.2%
Earnings growth rate
-4.2%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | -14.5% |
Return on equity | n/a |
Net Margin | -35.5% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Norris Medicines makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 54 | -19 | 20 | 0 |
30 Sep 23 | 79 | -18 | 23 | 0 |
30 Jun 23 | 84 | -19 | 25 | 0 |
31 Mar 23 | 84 | -17 | 23 | 0 |
31 Dec 22 | 80 | -34 | 22 | 0 |
30 Sep 22 | 63 | -34 | 21 | 0 |
30 Jun 22 | 55 | -36 | 22 | 0 |
31 Mar 22 | 94 | -33 | 23 | 0 |
31 Dec 21 | 112 | -42 | 26 | 0 |
30 Sep 21 | 143 | -43 | 31 | 0 |
30 Jun 21 | 153 | -48 | 32 | 0 |
31 Mar 21 | 123 | -50 | 31 | 0 |
31 Dec 20 | 110 | -23 | 30 | 0 |
30 Sep 20 | 81 | -28 | 29 | 0 |
30 Jun 20 | 67 | -26 | 29 | 0 |
31 Mar 20 | 78 | -28 | 32 | 0 |
31 Dec 19 | 101 | -14 | 35 | 0 |
30 Sep 19 | 142 | -20 | 37 | 0 |
30 Jun 19 | 145 | -14 | 46 | 0 |
31 Mar 19 | 163 | -17 | 38 | 0 |
31 Dec 18 | 159 | -25 | 40 | 0 |
30 Sep 18 | 154 | -20 | 44 | 0 |
30 Jun 18 | 148 | -24 | 36 | 0 |
31 Mar 18 | 136 | -25 | 49 | 0 |
31 Dec 17 | 148 | -32 | 51 | 0 |
30 Sep 17 | 164 | -26 | 54 | 0 |
30 Jun 17 | 198 | -14 | 56 | 0 |
31 Mar 17 | 205 | -8 | 54 | 0 |
31 Dec 16 | 212 | 0 | 53 | 0 |
30 Sep 16 | 204 | -2 | 52 | 0 |
30 Jun 16 | 194 | 0 | 50 | 0 |
31 Mar 16 | 189 | 0 | 49 | 0 |
31 Dec 15 | 181 | -12 | 60 | 0 |
30 Sep 15 | 190 | -8 | 56 | 0 |
30 Jun 15 | 186 | -13 | 55 | 0 |
31 Mar 15 | 187 | -10 | 41 | 0 |
31 Dec 14 | 99 | -15 | 26 | 0 |
31 Mar 14 | 207 | -15 | 50 | 0 |
Quality Earnings: 524414 is currently unprofitable.
Growing Profit Margin: 524414 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524414 is unprofitable, and losses have increased over the past 5 years at a rate of 4.2% per year.
Accelerating Growth: Unable to compare 524414's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 524414 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: 524414's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.